Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group

Next Previous
Trial Profile

Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary)
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COLUMBUS-AD
  • Sponsors Pierre Fabre

Most Recent Events

  • 30 Jun 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
  • 21 Nov 2023 Status changed from recruiting to active, no longer recruiting.
  • 31 Oct 2023 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top